306 related articles for article (PubMed ID: 37141550)
1. A Gene Panel Associated With Abemaciclib Utility in
Brett JO; Dubash TD; Johnson GN; Niemierko A; Mariotti V; Kim LSL; Xi J; Pandey A; Dunne S; Nasrazadani A; Lloyd MR; Kambadakone A; Spring LM; Micalizzi DS; Onozato ML; Che D; Nayar U; Brufsky A; Kalinsky K; Ma CX; O'Shaughnessy J; Han HS; Iafrate AJ; Ryan LY; Juric D; Moy B; Ellisen LW; Maheswaran S; Wagle N; Haber DA; Bardia A; Wander SA
JCO Precis Oncol; 2023 May; 7():e2200532. PubMed ID: 37141550
[TBL] [Abstract][Full Text] [Related]
2. Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.
Navarro-Yepes J; Kettner NM; Rao X; Bishop CS; Bui TN; Wingate HF; Singareeka Raghavendra A; Wang Y; Wang J; Sahin AA; Meric-Bernstam F; Hunt KK; Damodaran S; Tripathy D; Keyomarsi K
Cancer Res; 2023 Oct; 83(19):3264-3283. PubMed ID: 37384539
[TBL] [Abstract][Full Text] [Related]
3. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Damodaran S; O'Sullivan CC; Elkhanany A; Anderson IC; Barve M; Blau S; Cherian MA; Peguero JA; Goetz MP; Plourde PV; Portman DJ; Moore HCF
Ann Oncol; 2023 Dec; 34(12):1131-1140. PubMed ID: 38072513
[TBL] [Abstract][Full Text] [Related]
4. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.
Jiang H; Zhong J; Wang J; Song G; Di L; Shao B; Zhang R; Liu Y; Zhu A; Wang N; Li H
Cancer Med; 2024 May; 13(10):e7249. PubMed ID: 38770648
[TBL] [Abstract][Full Text] [Related]
5. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.
Wander SA; Han HS; Zangardi ML; Niemierko A; Mariotti V; Kim LSL; Xi J; Pandey A; Dunne S; Nasrazadani A; Kambadakone A; Stein C; Lloyd MR; Yuen M; Spring LM; Juric D; Kuter I; Sanidas I; Moy B; Mulvey T; Vidula N; Dyson NJ; Ellisen LW; Isakoff S; Wagle N; Brufsky A; Kalinsky K; Ma CX; O'Shaughnessy J; Bardia A
J Natl Compr Canc Netw; 2021 Mar; ():1-8. PubMed ID: 33761455
[TBL] [Abstract][Full Text] [Related]
8. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
9. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
11. Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment.
Iuliani M; Simonetti S; Ribelli G; Napolitano A; Longo UG; Vincenzi B; Orsaria P; Denaro V; Tonini G; Santini D; Francesco P
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269621
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
Kalinsky K; Accordino MK; Chiuzan C; Mundi PS; Sakach E; Sathe C; Ahn H; Trivedi MS; Novik Y; Tiersten A; Raptis G; Baer LN; Oh SY; Zelnak AB; Wisinski KB; Andreopoulou E; Gradishar WJ; Stringer-Reasor E; Reid SA; O'Dea A; O'Regan R; Crew KD; Hershman DL
J Clin Oncol; 2023 Aug; 41(24):4004-4013. PubMed ID: 37207300
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
14. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
15. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
16. Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
Seki H; Sakurai T; Sakurada A; Kinoshita T; Shimizu K
Anticancer Res; 2022 Feb; 42(2):1099-1106. PubMed ID: 35093912
[TBL] [Abstract][Full Text] [Related]
17. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
Martin JM; Handorf EA; Montero AJ; Goldstein LJ
Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Genomic Characteristics of Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors.
Rao X; Chen Y; Beyrer J; Nash Smyth E; Morato Guimaraes C; Litchfield LM; Bowman L; Lawrence GW; Aggarwal A; Andre F
Clin Cancer Res; 2023 Sep; 29(17):3372-3383. PubMed ID: 37289194
[TBL] [Abstract][Full Text] [Related]
19. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Xi J; Ma CX
Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
[TBL] [Abstract][Full Text] [Related]
20. First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study.
Basile D; Gerratana L; Corvaja C; Pelizzari G; Franceschin G; Bertoli E; Palmero L; Zara D; Alberti M; Buriolla S; Da Ros L; Bonotto M; Mansutti M; Spazzapan S; Cinausero M; Minisini AM; Fasola G; Puglisi F
Breast; 2021 Jun; 57():104-112. PubMed ID: 33812267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
